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Intercellular communication is a key
feature in physiological and patholog-
ical conditions. We hypothesize that
several means of intercellular commu-
nication occur either simultaneously
or in succession.
The most studied means of intercellular
communication are soluble factors.
However, important alternative meansIntercellular communication refers to the different ways through which cells
communicate with each other and transfer a variety of messages. These commu-
nication methods involve a number of different processes that occur individually
or simultaneously, which change depending on the physiological or pathological
context. The best characterized means of intercellular communication is the
release of soluble factors that affect the function of neighboring cells. However,
there are many other ways by which cells can communicate with each other.
Here, we review the different means of intercellular communication including
soluble factors in the context of senescence, ageing, and age-related diseases.are emerging.
Senescent cells are highly proactive and
communicate with neighboring cells via
various means of intercellular communi-
cation including but not limited to the
senescence-associated secretory phe-
notype (SASP).
Most studies of pharmacological drugs
preventing the release of soluble factors
oversee the influence of these drugs on
other means of communication.
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The discovery of a cellular phenotype termed senescence (see Glossary) was first identified by
Moorehead and Hayflick in the 1960s. When culturing in vitro primary fibroblasts isolated from
human donors, they observed that these cells reached a point where they lost their proliferative
capacity, and termed this phenotype cellular senescence. Cleverly, they hypothesized that this
phenotype could mimic ageing and be exploited as ‘ageing in a Petri dish’ [1,2]. The premature
induction of senescence termed oncogene-induced senescence was identified in vitro and
later confirmed to play a physiological role in preventing tumor progression in vivo [1,3].
However, it was not until 2011 that the van Deusen laboratory established a causative role
between the activation of senescence and ageing [4]. Here, the authors established that the
accumulation of p16Ink4a in certain organs in a prematurely aged mouse model deficient for
the mitotic checkpoint protein BubR1 triggers natural features common in premature ageing.
Interestingly, they showed for the first time that genetic inactivation of p16Ink4a ameliorated
these ageing phenotypes [4]. It is now well established that the induction of cellular senescence
is a hallmark of ageing [5]. Furthermore, senescence is a driver not only of ageing but also of
certain age-related diseases such as cancer, osteoarthritis, atherosclerosis, Alzheimer’s
diseases, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary
fibrosis (IPF) among others [6–11].
Although themain characteristic of senescence is a stable cell cycle arrest induced by the expres-
sion of the cell cycle inhibitors p16INK4A and p21CIP, the influence that senescence has on tissue
homeostasis is due to its highly proactive secretome. The senescence-associated secretory
phenotype (SASP) could be considered the ‘soul’ of senescence as it is highly proactive and it
changes its composition with time. It has both beneficial and detrimental effects depending on the
trigger and context where senescence is induced [12,13]. However, the SASP is still not well
characterized, as only a number of factors have been identified in very specific scenarios. It is
important to note that senescence is a complex heterogeneous cellular phenotype that affects
tissue homeostasis in many different contexts and caution should be taken when it is standard-
ized to certain markers (Box 1). It is likely that there remain novel, unveiled characteristics of
senescence that are context dependent [14].628 Trends in Cell Biology, August 2020, Vol. 30, No. 8 https://doi.org/10.1016/j.tcb.2020.05.003
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Glossary
Ferroptosis: cellular death induced by
accumulation of iron in the cell.
Inflammaging: chronic, low-grade
inflammation characteristic of aging.
Inflammasome: congregation of
immune system receptors that activate
caspase-1 and induce an innate
inflammatory response.
Senescence: activation of a phenotype
characterized by several biomarkers
including stable cell cycle arrest and a
proactive secretome.
Senescence-associated secretory
phenotype (SASP): soluble factors,
growth factors, and matrix remodeling
enzymes secreted by cells undergoing
senescence.
Senolytic drugs: drugs designed to
specifically kill senescent cells.
Senomorphics: chemicals or drugs
that inhibit the sSASP.
Syncytiotrophoblast: outer layer of
the placenta formed by the fusion of
trophoblast cells.
Trans-stable-isotope labelling of
amino acids in cell culture (SILAC):
transfer of proteins between cells using
SILAC.
Trends in Cell BiologyThere are currently twomain therapeutic strategies to deal with the presence of senescent cells in
ageing and age-related diseases. One relates to the potential for selective killing of senescent
cells (using pharmacological compounds termed senolytics). The second aims to neutralize
the deleterious effects of intercellular communication, in particular the SASP, on senescent
cells by using drugs denominated senomorphics. Here, we review the different means of inter-
cellular communication for senescent cells and their relation to ageing and some age-related
diseases, classifying them as classical, emerging, and nonclassical. We include soluble factors
and extracellular matrix (ECM) remodeling proteins, but also describe additional ways by which
cells communicate.We focus on how intercellular communication is regulated and its functionality
in different biological and age-related pathological contexts.
SASP: Classical and Nonclassical Intercellular Communication
The SASP is ameans of intercellular communication that specifically refers to senescent cells. The
classical SASP is characterized by soluble factors, growth factors, and ECM remodeling enzymes
[12]. However, emerging SASP and other means of intercellular communication that we have
denominated nonclassical have also been described during senescence and ageing. Here, we
review the current knowledge on what we call classical, emerging, and nonclassical SASP.
Classical SASP: Soluble Factors or sSASP
The sSASP can be both beneficial and detrimental for tissue homeostasis; therefore, the sSASP
needs to be tightly regulated. One of the main drivers of the sSASP is a persistent DNA damage
response [15]. This converges in the activation of two major regulators of the SASP: NF-κB and
C/EBPβ, where NF-κB is further regulated by the transcription factor GATA4 (Figure 1A) [16].
However, the sSASP can also be induced independent of a noncanonical DNA damage response
by p38MAPK [17] and by the presence of cytoplasmic chromatin fragments (CCFs). These are
DNA fragments that can be released from the nucleus during senescence and activate the anti-
viral cyclic GMP-AMP synthase (cGAS) stimulator of interferon genes (STING) pathway [18,19].
Still, both p38MAPK and CCF activate the sSASP via NF-κB signaling.
Curiously, activation of the inflammasome can also control the sSASP. This is mediated by in-
terleukin (IL)-1 signaling and IL-1α expression and is mainly involved in paracrine senescence sig-
naling [20]. Furthermore, IL-1A is regulated by mammalian target of rapamycin (mTOR) inhibition.Box 1. Guidelines to Identify Senescent Cells In Vitro
Cellular senescence can be induced by a variety of triggers, including telomere shortening, oncogenic stress, ROS, and
DNA damage. The main response of primary cells entering senescence is to induce a stable cell cycle arrest by expressing
the cell cycle inhibitors CDKN2A, CDKN2B, and/or CDKN1A (encoding p16INK4A, p15INK4B, and/or p21CIP proteins,
respectively) and showing a lack of proliferation-related markers such as Ki67, BrdU, or EdU (Figure I) [13,14]. However,
as these markers are not exclusive to senescent cells but are also present in nondividing somatic cells, additional markers
should be used to confirm a senescent phenotype [89]. The identification of more than three biomarkers is recommended
to confirm the activation of senescence. Another marker used to identify senescence is senescence-associated beta
galactosidase (SA-β-Gal) activity. An increase in SA-β-Gal is due to higher lysosomal activity in senescent cells, which
could be due to an increase in the number of lysosomes in senescence [37] or an increase in lysosomal activity and can
be detected by a specific stain. Finally, additional markers such as DNA damage, the release of a particular secretome that
has been termed the SASP [12], or the activation of specific signalling pathways should also be verified. However, these
last markers are slightly more challenging as some triggers, such as oncogene-induced senescence by H-RasG12V ex-
pression, induce all of them simultaneously. Instead, other triggers, such as developmental senescence or an increase
in αvβ3, do not induce a DNA damage response, which was long believed to be a key biomarker of senescence
[65,73,74]. This confirms that not all biomarkers are expressed simultaneously when senescence is induced, adding intri-
cacy to the identification of senescence.
It is important to note that senescence is an extremely complex and heterogeneous cellular phenotype that affects tissue
homeostasis in many different contexts, and the generalization of standardized markers might be disadvantageous as it is
likely that there are as-yet-unveiled characteristics of senescence that are context dependent [14].
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Figure I. Biomarkers of Senescence. Abbreviations: EV, extracellular vesicle; mTOR, mammalian target of rapamycin;
SA-β-Gal, senescence-associated beta galactosidase; SASP, senescence-associated secretory phenotype; TGF-β,
transforming growth factor β.
Trends in Cell BiologymTOR selectively regulates a number sSASP factors post-transcriptionally via IL-1A, but also
through MK2 [mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2)] by the
protein synthesis factor 4EBP1 [21,22].
Alternatively, epigenetic alterations are also known to regulate the sSASP. A recent study found
that derepression of the retrotransposable element line 1 (L1) increased during senescence
and ageing. This in turn activated cGAS/STING and, consequently, the sSASP [23]. Furthermore,
the sSASP is regulated by global chromatin remodeling and the recruitment of BRD4 to
superenhancers near sSASP genes [24]. Overall, the sSASP is tightly regulated as dysfunctional630 Trends in Cell Biology, August 2020, Vol. 30, No. 8
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Figure 1. Intercellular Communication in Senescence and Ageing. (A) Soluble factors, growth factors, and matrix remodeling enzymes are released in the classical
soluble senescence-associated secretory phenotype (sSASP) model. However, the sSASP needs to be tightly regulated. At the transcriptional level, BRD4 and GATA4
regulate the master regulators of the SASP: NF-κB and C/EBPβ. The sSASP can also be driven by LINE-1 (L1) retrotransposable elements that are derepressed during
senescence and by cytoplasmic chromatin fragments (CCFs) through the activation of cyclic GMP-AMP synthase (cGAS). The sSASP is also regulated post-
transcriptionally by mammalian target of rapamycin (mTOR) and downstream signalling pathways. The secreted sSASP plays many roles in the microenvironment. On
the one hand, it alters the extracellular matrix (ECM) and can reinforce senescence through autocrine signalling. On the other hand, it has many functions through
paracrine signalling. It can promote cancer progression, stem cell self-renewal, and stem cell-like features in damaged cells. It also has the ability to transmit
senescence to neighboring cells. Importantly, the sSASP stimulates an innate and adaptive immune response favoring the elimination of senescent cells. (B) Emerging
SASP factors include extracellular vesicles (EVs) (evSASP). Due to the high heterogeneity and cargo diversity of EVs released during senescence, novel functions are
continually emerging. Some cargo factors, such as interferon (IFN) and ephrin-related and antioxidant proteins, are highlighted. In addition, miRNAs (miRs) and CCF
DNA fragments can be loaded into evSASPs. evSASPs also exert paracrine functions to promote cancer progression and induce paracrine senescence. Furthermore,
metabolites and lipid mediators that induce an oxidative microenvironment or favor tumor progression have been found. Gut microbiota release lipoteichoic acid (LTA)
and deoxycholic acid (DCA), which drive a sSASP response via COX-2 and prostaglandin E2 (PGE2) release. (C) Nonclassical SASP refers to intercellular
communication in senescence not driven by released factors. Cell-to-cell communication can be mediated via receptor interaction as with interleukin-1 receptor (IL-1R)
and interleukin-1 alpha (IL-1A) or via NOTCH1/JAG interaction, both of which induce sSASP. In addition, cell–ECM interaction has been described in senescence. For
example, integrin α6β1 can interact with CCN1 (cysteine-rich protein 1) and induces senescence via reactive oxygen species (ROS) while αvβ3 induces sSASP.
Alternatively, cytoplasmic extensions called cytoplasmic bridges also occur during senescence. Interestingly, these have been described between senescent cells and
natural killer (NK) cells to activate these and promote the elimination of senescent cells. The fusion of cells can also induce senescence allowing material exchange
between the fused cells. Furthermore, senescent cells can engulf cancer cells as a source of energy to maintain the high metabolic requirements of senescent cells.
Abbreviations: eNAMPT, extracellular nicotinamide phosphoribosyltransferase; EphA2, ephrin A2; IFITM3, interferon-induced transmembrane protein 3; LTBP, latent
TGF-binding protein.
Trends in Cell Biologyexpression and release can drive pathological conditions. This highlights the importance of
understanding how the sSASP is regulated.
It was long believed that the sSASP would change in composition throughout time. Thus, it was
not until recently that a comprehensive study found the sSASP to comprise two distinctive func-
tional waves [25]. The first wave is formed by an anti-inflammatory transforming growth factorTrends in Cell Biology, August 2020, Vol. 30, No. 8 631
Trends in Cell Biology(TGF)-β-enriched sSASP. This particular sSASP is regulated by membrane-bound NOTCH1,
whose expression increases during the initial stages of the induction of senescence andmediates
C/EBPβ repression. Second and through time, NOTCH1 expression decreases causing the
activation of C/EBPβ, which in turn induces a proinflammatory sSASP [25].
Our advancement of knowledge of the sSASP has greatly increased, with many novel roles
emerging in the past decades. On the one hand, the sSASP is important for reinforcing a stable
cell cycle arrest in an autocrine manner through IL-8 and IL-6 and their corresponding receptors
(Figure 1A) [26,27]. On the other hand, it acts in a paracrine fashion influencing a variety of cell
types. It can induce senescence in primary fibroblasts and epithelial cells [20], while promoting
tumorigenesis in cancer cells [13,14,28]. Importantly, the sSASP also acts in a paracrine fashion
by mediating both an innate and an adaptive tissue response favoring the removal of senescent
cells from the tissue, which is essential for the maintenance of tissue homeostasis [20,29,30].
More recently, the SASP was shown to be key for tissue regeneration via IL-6 [31,32] and cell
plasticity and stemness [33,34]. Despite many recent advances in novel roles and regulation of
the sSASP, there are also emerging functions as described next.
Emerging Classical SASPs
Although the SASP is classically defined as the secretome released from senescent cells, most of
the current literature focuses on soluble factors, growth factors, and ECM remodeling enzymes.
In this section, we aim to review emerging literature on novel SASP components such as
extracellular vesicles (EVs) and noncellular metabolites and ions (Figure 1B).
EVs are lipid membrane vesicles that are released by all cells and are therefore found in most
biological fluids [35]. Although initially thought of as a mechanism to release unwanted compo-
nents from the cell, they are now recognized as a well-established mechanism for intercellular
communication. Despite this, senescent cells remove toxic cytoplasmic DNA via EVs to maintain
cellular homeostasis [36]. Indeed, senescent cells release more EVs (evSASP) than proliferating
cells [36–40]. Interestingly, it has been shown that these EVs induce paracrine senescence in
healthy cells, highlighting their importance as intercellular communication mediators (Figure 1B)
[37,39]. While the mechanisms responsible for this are unknown, several miRNAs, interferon-
related proteins, and antiapoptotic proteins were found enriched in senescent-derived EVs
[37,39–42]. By contrast, a protumorigenic role for EVs derived from senescent cells mediated
by ephrin A2 (EphA2) has been suggested [38] adding an extra layer of complexity to the evSASP.
Interestingly, several ephrin-related proteins are enriched in plasma derived from old healthy do-
nors [43,44], although whether they are free proteins or EV associated remains to be determined.
Metabolites are small chemical byproduct molecules of metabolic activity in cells and tissues that
provide functional evidence of biochemical activity [45]. Thus, several metabolites are emerging
as biomarkers of senescence, ageing, and related diseases. Interestingly, metabolite regulators
have also been found inside EVs conferring intrinsic metabolic activity on EVs [90]. For example,
extracellular nicotinamide phosphoribosyltransferase (eNAMPT), a regulator of NAD+, was found
in EVs and decreased with ageing in mice and humans. Furthermore, EV-contained eNAMPT in-
creased NAD+ levels in recipient cells, delaying ageing and extending lifespan in mice [46]. Inter-
estingly, NAMPT has been shown to regulate the SASP [47].
The extracellular metabolite profile differs between young and elderly individuals. Analysis of
blood from old donors (N74 years old) showed a reduction in metabolites related to antioxidants,
redox, and muscle maintenance [48]. Levels of the antioxidant molecule NAD+ decrease in
various tissues, including plasma [49], during ageing [50,51], which correlates with the reduction632 Trends in Cell Biology, August 2020, Vol. 30, No. 8
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Together these findings are associated with the extracellular metabolic profile of senescent cells,
where an increase in citrate and metabolites involved in oxidative stress were found [53]. Citrate,
however, can be found associated with iron in the blood. The levels of iron are generally increased
in ageing and age-related diseases as Alzheimer’s and Parkinson’s, leading to the generation of
reactive oxygen species (ROS). ROS, lactate, ketones, glutamine, and nitric oxide (NO) are all
high-energy metabolites released by senescent cells producing a toxic surrounding microenvi-
ronment [54]. Given that ions and metabolites have been poorly characterized in senescence
and ageing, it will be critical to further understand their implications as emerging components
of the SASP.
Lipid mediators involve a family of molecules implicated in anti- and proinflammatory mecha-
nisms that also enhance microbial clearance [55]. A recent study found that the obesity-
related gut microbiota components lipoteichoic acid (LTA) and deoxycholic acid (DCA) induce
senescence in hepatic stellate cells (HSCs), promoting hepatocellular carcinoma (HCC) pro-
gression [56,57]. Interestingly, LTA induced the release of the lipid metabolite prostaglandin
E2 (PGE2) via COX-2 and suppressed the antitumor immunity. It would be interesting to determine
whether other lipid mediators are implicated in tissue homeostasis maintenance as part of the
emerging SASP.
Nonclassical Intercellular Communication
In this section, we review other means of intercellular communication beyond soluble and
emerging factors that are also important during senescence and ageing. We call these nonclas-
sical (or not secreted) mechanisms for intercellular communication (Figure 1C).
Juxtacrine signaling is a means of intercellular communication characterized by cells involving
ligand–receptor binding. Senescent cells also communicate with their neighbor cells through
cell-to-cell or juxtacrine contact. For example, IL-1A, thought to be a master regulator of soluble
factor paracrine senescence [20], also regulates juxtacrine senescence [58]. Senescent cells
express membrane-bound IL-1A, which interacts with the IL-1R to control the levels of IL-6
and IL-8; thus, downregulation of IL-1R or IL-1α using RNAi or blocking antibodies prevents
the upregulation of IL-6 and IL-8 during senescence (Figure 1C) [58]. Furthermore, in an elegant
study Hoare et al. showed that membrane-bound NOTCH1 expression regulates the composi-
tion of the SASP, which they found to be highly dynamic [25]. Although NOTCH1 initially drives a
classical TGF-β-enriched secretome, it also contributes to senescence mediated by cell-to-cell
contact through the juxtacrine NOTCH/JAG pathway in a lateral induction fashion [59]. This
has been defined as secondary juxtacrine senescence, where NOTCH1 is essential for the trans-
mission of senescence through cell-to cell signaling but not for paracrine senescence mediated
by soluble factors or cell-autonomous senescence [60].
It is known that sSASP can induce ECM remodeling and stiffening, which can alter immune cell
recruitment in ageing [54]. Although it is acknowledged that senescent cells secrete a variety of
ECM remodeling proteins, the interaction of the senescent cell with the ECM is less well
described. Senescence can be induced by the interaction between the integrin α6β1 and the
matricellular protein CCN1 during wound healing, inflammation, fibrosis, heart regeneration,
and cancer, activating ROS [61–64]. Furthermore, integrin αvβ3 was also shown to induce
senescence by activation of the TGF-β pathway in a cell-autonomous and non-cell-autonomous
fashion [65,66]. However, although ROS release was induced, there was no DNA damage
associated, suggesting that the ECM–cell interaction can induce senescence via different
mechanisms.Trends in Cell Biology, August 2020, Vol. 30, No. 8 633
Trends in Cell BiologyCell-to-cell fusion is a means of intercellular communication that can be induced upon the aber-
rant expression of fusogenic proteins or in response to viral infection such as with measles or
ERVWE1 expression [67]. It induces senescence in response to fusion and mediates an immune
response not only in primary but also in cancer cells. Although the mechanisms implicated remain
to be elucidated, p53 is partially needed for the induction of senescence by fusion in cancer cells
[68]. One of the pathological conditions where cell fusion has been observed is cancer [67].
Interestingly, the activation of senescence by chemotherapy in cancer cells stimulates them to
‘engulf’ neighboring cells, which are later processed through the lysosome. This provides these
cells with material and energy to sustain the required high metabolic capacity of senescent
cells [69]. However, the mechanisms behind this and whether this is a form of cell fusion would
need to be further addressed.
Besides cell fusion, cytoplasmic bridges also allow the exchange of biological material between
cells, including RNA, proteins, and even organelles such as mitochondria and lysosomes
[70,71]. Cytoplasmic bridges are membrane extensions that allow spatiotemporal interaction be-
tween nearby cells. The transfer of materials between cells has been proved in diverse cell types,
such as neurons, cancer cells, and immune cells, but also senescent cells [70,71]. By performing
trans-stable-isotope labelling of amino acids in cell culture (SILAC), Biran et al. showed
that senescent cells transfer protein material to natural killer (NK) cells through cytoplasmic
bridges mediating their activation and increased cytotoxicity [70]. The transfer is dependent on
the GTPase CDC42 and the proteins transferred are mainly involved in actin cytoskeleton reorga-
nization and antigen presentation, although certain proteins important for the activation of NK
cells such as HSPA5 and CALR were also found. Interestingly, protein transfer also happens
in vivo [70], clear whether the transfer is mediated exclusively by cytoplasmic bridges or by addi-
tional intercellular communication mechanisms.
Intercellular Communication in Physiology and Pathology
Together, the described studies show the importance of the contribution of classical, emerging,
and nonclassical intercellular communication occurring during senescence and ageing. Although
we have categorized themeans for intercellular communication in the different sections, the reality
is that it is extremely likely that a simultaneous combination of some, if not all, is what occurs
in vivo, which will further depend on the biological or pathological context. Here, we review
which means of communication are known for senescence in a particular physiological or
pathological scenario. In addition, we discuss described communication types where we can
hypothesize a role for senescence in particular contexts.
Intercellular Communication Contributes to Tissue Homeostasis Maintenance
The development of the placenta is an important step during pregnancy. One of the outer layers
of the placenta is the syncytiotrophoblast that is formed by the fusion of trophoblast cells. This
fusion induces the activation of senescence in vitro and several markers of senescence have been
observed in this structure in vivo [68]. Although it is unclear why cells in the syncytiotrophoblast
become senescent, it is speculated that it could be a mechanism to prevent apoptosis or contrib-
ute to maternal–embryonic transport in the placenta [68]. EVs from trophoblast cells have been
shown to deliver miR-enriched EVs to non-trophoblast cells to protect against viral infections
by inducing autophagy [72]. Together with the ability of senescent cells to develop cytoplasmic
bridges, these mechanisms seem to potentiate the exchange of materials between cells during
development (Figure 2A, top panel) [70,72].
Senescence is a normal process during development, where the sSASP plays a key role inmediating
the clearance of these cells by macrophages to ensure the correct formation of the embryo [73,74].634 Trends in Cell Biology, August 2020, Vol. 30, No. 8
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Figure 2. Intercellular Communication in Physiology and Age-Related Pathology. (A,B) Different types of
intercellular communication have been described that can be (A) beneficial or (B) detrimental for tissue homeostasis and
organism wellbeing. Blue boxes indicate that there is scientific evidence for a correlation between that type of intercellular
communication and senescence; orange boxes show scientific evidence for the indicated particular physiological or
pathological situation but not in the context of senescence. Abbreviations: ECM, extracellular matrix; evSASP, extracellular
vesicle senescence-associated secretory phenotype; sSASP, soluble senescence-associated secretory phenotype.
Trends in Cell BiologyThe sSASP induces tissue remodeling and regeneration, a process in which cell fusion plays a critical
role [75]. Interestingly, TGF-β as part of the sSASP seems to be key for senescence during develop-
ment [73]. As integrins and NOTCH signaling regulate TGF-β in senescence [25,65] and both play
key roles in development [76,77], it would be interesting to understand whether juxtacrine and
ECM–cell intercellular communication occur in senescent cells at this time.
In certain scenarios such as wound healing and fibrosis, senescence is activated to prevent
hyperproliferation and excessive scar formation [3,61,62]. Senescence can be mediated by
contact with the ECM protein CCN1 via integrin α6β1, inducing a ROS-induced senescence re-
sponse during wound healing and liver fibrosis (Figure 2A, bottom panel) [61,62]. Furthermore,
the sSASP factor platelet-derived growth factor AA (PDGF-AA) released by senescent cells in
the wound accelerates healing [78]. Meanwhile, the activation of senescence in liver HSCs
recruits NK cells and tumor-inhibiting M1 macrophages to promote tissue resolution in fibrosis,
in a p53-dependent manner [3]. Interestingly, EVs also contribute to the acceleration of wound
healing closure and scar formation reduction in animal models [79], while increased NAD+
protects against bleomycin-induced lung fibrosis [51]. Overall, during wound healing and fibrosis
a combination of intercellular communication processes are described in the form of soluble and
growth factors, EVs, metabolites, and interactions with the ECM, although more experimental
evidence would be needed to determine the implications of their coexistence in senescence.Trends in Cell Biology, August 2020, Vol. 30, No. 8 635
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Although the incidence of cancer increases with ageing, there are already many reviews describ-
ing intercellular communication in cancer and it is therefore beyond the scope of this review
[14,76,80]. Here, we review ageing and age-related neurodegenerative and inflammatory
diseases.
One of the mayor changes occurring in ageing is a dysfunctional inflammatory response termed
‘inflammaging’, where most of the inflammatory factors described are also part of the sSASP
[5]. During ageing there is an accumulation of senescent cells, which chronically release sSASP
factors. This, together with a defective immune system inefficient in eliminating senescent cells,
contributes to inflammaging and tissue damage in ageing [5]. However, not only the sSASP con-
tributes to age-related dysfunction. An altered ECM due to changes in matrix stiffness impairs the
access of immune cells to senescence-enriched tissues [54]. As a consequence, this impairs the
interaction of senescent cells with the ECM, affecting homeostatic processes such as prolifera-
tion, apoptosis, and migration [66,76]. Interestingly, NOTCH1 expression levels decrease during
ageing, which could partially explain the chronic proinflammatory SASP via C/EBPβ activation if
the molecular mechanism were conserved between cancer and ageing [25].
During ageing, the number of hypothalamic stem/progenitor cell decreases inducing an ageing-
related phenotype in mice. However, treatment of old mice with EVs derived from young progen-
itor cells ameliorates age-related functions in the hypothalamus by preventing the decrease in theTrends in Cell Biology
Figure 3. Pharmacological Manipulation to Prevent Intercellular Communication. Various pharmacologica
inhibitors have been described to prevent intercellular communication in senescence and ageing. The best characterized
pharmacological drugs are those targeting the soluble senescence-associated secretory phenotype (sSASP). The sSASP
can be neutralized by preventing common upstream master regulators such as GATA4, NF-κB, or BRD4. Alternatively
inhibitors can target other pathways involved in the release or processing of the sSASP, such as the mammalian target o
rapamycin (mTOR) pathway. Additionally, individual components of the emerging SASP can be prevented using particula
pharmacological drugs that block, for example, extracellular vesicle SASP (evSASP) release or prostaglandin E receptor 4
(PTGER4) binding to prostaglandin E2 (PGE2). The nonclassical SASP can also be inhibited by preventing the NOTCH
JAG pathways, integrin signaling, or the formation of cytoplasmic bridges. Abbreviations: BET, bromodomain and
extraterminal inhibitors; DAPT, N-[(3,5-difluorophenyl)acetyl]-L-alanyl-2-phenylglycine-1,1-dimethylethyl ester; LatA
latrunculin A; NAC, N-acetyl cysteine.
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Trends in Cell Biologynumber of these cells via miR-contained EVs [41]. Similarly, old mice treated with eNAMPT-
enriched vesicles – characteristic of young mice – also show delayed ageing [46], suggesting
that EVs might target multiple pathways in old recipient cells [90]. Whether this is due to EV het-
erogeneity or to other, additional mechanisms remains to be determined. The role of EVs during
ageing is still not well characterized.
Although metabolites and ions can be found in EVs, they are also present as extracellular mole-
cules. During ageing there is an increase in the release of oxidative molecules such as NO and
ROS concurrent with a decrease in those with an antioxidant capacity such as NAD+. Together
this produces an increase in oxidative stress, a driver for many hallmarks of ageing and senes-
cence (Figure 2B, top panel) [5].
It is hypothesized that one of the consequences of ageing and related diseases is the accumula-
tion of senescent cells and their active intercellular communication profile. For example, the use of
senolytics shows amelioration of certain disease-related features in various neurodegenerative
pathologies (e.g., Alzheimer’s [11], Parkinson’s [9,81]). As described before, many different
means of intercellular communication are involved during ageing, with an inflammatory sSASP
being the best characterized. Neurodegenerative diseases like Alzheimer’s and Parkinson’s are
associated with chronic inflammation [82]. However, the release of ROS and reactive nitrogen
species together with a decrease in antioxidants also greatly contributes to these pathologies
[46,50,82]. Together this can increase Aβ deposition in Alzheimer’s and α-synuclein truncation
and aggregation in Parkinson’s [82]. Interestingly, Aβ and α-synuclein can be transmitted to
neighboring cells via EVs [35,83] or by cytoplasmic bridges in the case of α-synuclein [84].
Although the transfer of misfolded proteins contributes to neurodegeneration in these diseases,
the release of ions such as iron also seems to contribute. Iron accumulation can be found in
brain sections of multiple neurodegenerative diseases [85,86] stimulating microglia, NF-κB
activation, and the release of proinflammatory cytokines [85]. Conversely, iron dysfunction
leads to a form of cell death termed ferroptosis. Interestingly, senescent cells accumulate iron
and suffer changes in the metabolism of iron [87]. As the transferrin receptor (a transporter of
iron) has been found in EVs, it is tempting to speculate a role for EV in the transfer of iron in senes-
cence, although more experimental evidence is needed (Figure 2B, bottom panel) [72].
A causative role for senescence has been found in many age-related inflammatory diseases, such
as IPF, osteoarthritis, and atherosclerosis, where chronic inflammation is well characterized. This
is concomitant with the release of oxidative molecules and decrease of antioxidant metabolites. It
is known that NAD+ levels are reduced in atherosclerosis, neurodegeneration, and sarcopenia
[50]. Interestingly, in a recent study Jeon and colleagues found that EVs released from senescent
chondrocytes transfer this phenotype to proliferating chondrocytes, inhibiting cartilage formation
and contributing to an inflammatory environment in osteoarthritis [39]. The role of EVs in inflam-
matory diseases is highly important due to their immunoregulatory potential by either activating
or inducing immunosuppression depending on the context. For example, EVs isolated from the
synovial fluid of rheumatoid arthritis patients contribute to joint inflammation [72,88], while
tumor-derived EVs have been shown to induce a tumor suppressive environment by inducing
apoptosis in T cells via CD95 ligand (CD95L), tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRIAL), or Galectin 9 [72,80].
Concluding Remarks and Future Directions
Recent experiments in mice have confirmed a causative, detrimental role for senescent cells in
several pathologies. The selective removal of senescent cells by treatment with various senolytics
has shown that their elimination improves tissue homeostasis and ameliorates diseaseTrends in Cell Biology, August 2020, Vol. 30, No. 8 637
Trends in Cell Biologysymptoms. The main culprit for the pathological effect of senescent cells in these contexts is
thought to be the SASP. However, as senescent cells are also important for tissue homeostasis
under physiological conditions, these drugs must be used with caution. An alternative approach
to prevent the damaging effect of senescent cells is by controlling or neutralizing the SASP
(Figure 3). The sSASP can be blocked following various approaches, such as preventing the ac-
tivation of main upstream regulators such as GATA4, NF-κB, and BRD4. Alternatively, inhibition of
the secretion or processing of the sSASP can be avoided using pharmacological drugs targeting,
for example, the mTOR pathway. Finally, preventing the signaling of individual sSASP factors can
be considered another strategy to avoid the functions of the sSASP. However, as reviewed here,
intercellular communication in senescence is much more complex than initially thought and
does not exclusively rely on soluble factors. It is therefore likely that other, currently unidentified
means of communication exist, highlighting the need for systematic identification and analysis
of alternative means of intercellular communication in senescence and ageing (see Outstanding
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